+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eptifibatide"

Eptifibatide Market - Global Forecast 2025-2032 - Product Thumbnail Image

Eptifibatide Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 199 Pages
  • Global
From
From
Eptifibatide API Market - Global Forecast to 2030 - Product Thumbnail Image

Eptifibatide API Market - Global Forecast to 2030

  • Report
  • August 2025
  • 191 Pages
  • Global
From
Myocardial Infarction Market Report 2025 - Product Thumbnail Image

Myocardial Infarction Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Eptifibatide is a cardiovascular drug used to treat acute coronary syndrome (ACS). It is a glycoprotein IIb/IIIa inhibitor, which works by blocking the action of platelets in the blood, preventing them from forming clots. It is administered intravenously and is usually used in combination with other drugs such as aspirin and heparin. Eptifibatide is used to reduce the risk of death, heart attack, and stroke in patients with ACS. It is also used to reduce the risk of recurrent ischemic events in patients with unstable angina or non-ST-segment elevation myocardial infarction. Eptifibatide is available in the market as a generic drug and is also sold under the brand names Integrilin and Reopro. It is manufactured by several pharmaceutical companies, including Merck, Pfizer, and Bristol-Myers Squibb. Show Less Read more